Search results for: Innovation Policy Prize
Filter search results
New: 50 Years of OHE Publications Are Available Online
2 April 2012
…Since the early days of the OHE, another key issue has been how best to define, encourage and evaluate innovation in medicine and medicines. Although perspectives and approaches have evolved,…
Register Now for the OHE Conference on Drug Development in 2022
2 July 2012
…The conference also will consider how to position the UK to retain and attract R&D. Speakers and panelists include thought leaders in the sciences and health policy from the UK…
OHE Conference on Drug Development in 2022: Update
18 July 2012
…Innovations, University of Oxford Professor Sir Alasdair Breckenridge, Chairman of the UK Medicines and Healthcare products Regulatory Agency (MHRA) Professor Patricia Danzon, Celia Moh Professor, Professor of Health Care Management,…
Spotlight on OHE: Value Based Pricing and New Technologies
31 December 2012
…Towse participated in a workshop organised by The Centre for Innovation in Regulatory Science (CIRS) that focused on companion diagnostics. His session focused on whether companion diagnostics will become the…
R&D Cost Drivers to be Explained by OHE Expert
18 January 2013
Jorge Mestre-Ferrandiz, lead author on OHE’s recent report on the cost of developing new drugs, will be discussing the important cost drivers at an upcoming UCL Vision seminar in London…
Changes in Determining Medicines Pricing in France, Germany and the UK
24 January 2013
…(VBP) is about the weighting given to the evidence and the social value of a drug. Overall, emphasis is increasing on “proving” innovation and/or an additional health benefit for a…
New OHE Study Compares Decisions by Five HTA Agencies on Oncology Meds
31 January 2013
Just out in the International Journal of Technology Assessment in Health Care is an important new study that reviews appraisals of breast cancer and colorectal cancer medicines by HTA agencies…
Reasons for Discontinuation of R&D Projects: Lead and Follow-on Indications
12 March 2013
The reasons for discontinuation of R&D projects in the biopharmaceutical industry are often a matter of conjecture. In a recent presentation to the 25th Annual EuroMeeting of the Drug Information…
Realising the Value of Medical Research: Health and Economic Benefits
20 March 2013
…(2012) The many faces of innovation. Second edition. London: Association of the British Pharmaceutical Industry. OHE and RAND Europe. (2010) Enhancing the benefits from biomedical and health research spillovers. Occasional…